The exclusive license covers the delivery and use of sustained-release exenatide, a GLP-1 receptor agonist, in the treatment of neurodegenerative disorders, including Parkinson's and Alzheimer's diseases.
This intellectual property was developed as part of a Cooperative Research and Development Agreement (CRADA) between Peptron and the NIH to develop and advance a form of exenatide that effectively crosses the blood-brain barrier and provides sustained release of the neuroprotective peptide to treat degenerative diseases of the central nervous system.
Peptron has developed fundamental technologies for creating sustained-release formulations to develop patient-friendly peptide-based medicines with a high technological entrance barrier and excellent product competitiveness for the treatment of life-threatening and chronic diseases.
Peptron is headquartered in Daejeon, Korea with GMP manufacturing facilities in Osong, Korea.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study